The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
B | Blood and blood forming organs | |
2
|
B01 | Antithrombotic agents | |
3
|
B01A | Antithrombotic agents | |
4
|
B01AE | Direct thrombin inhibitors | |
5
|
B01AE06 | Bivalirudin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| PAREN | Parenteral | 0.25 g |
| Active Ingredient |
|---|
|
Bivalirudin is a direct and specific thrombin inhibitor that binds both to the catalytic site and the anion-binding exosite of fluid-phase and clot-bound thrombin. |
| Document | Type | Information Source | |
|---|---|---|---|
| ANGIOMAX Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| Angiox 250mg powder for concentrate for solution for injection or infusion | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.